Clinical Trial Applications: Filter, Search, and view applications
| # | Protocol No | Study Title | Investigator(s) & Site(s) | |
|---|---|---|---|---|
291. |
ECCT/19/03/01 | Validation of syringe extension device Validation of re-usable, low cost syringe extension device for the provision of paracervical analgesia during gynecological procedures |
Principal Investigator(s) 1. Stephen Gwer 2. Aparna Ramanathan Site(s) in Kenya 1. Jaramogi Oginga Odinga Teaching and Referral Hospital (Kisumu county) 2. Kisumu County Hospital (Kisumu county) 3. God\'s Will Clinic (Kisumu county) 4. Marie Stopes Kenya-Kisumu Clinic (Kisumu county) |
View |
292. |
ECCT/14/11/02 | A5297 An Open-Label, Proof of Concept, Randomized Trial Comparing a LPV/r-Based to an nNRTI-Based Antiretroviral Therapy Regimen for Clearance of Plasmodium falciparum Subclinical Parasitemia in HIV-infected Adults with CD4+ Counts >200 and < 500 cells/mm3 |
Principal Investigator(s) 1. VICTOR AKELO Site(s) in Kenya KEMRI/CDC CLINICAL RESEARCH CENTRE |
View |
293. |
ECCT/23/11/05 | Alma Study Feasibility clinical study of the Alma system in treating Primary Postpartum Hemorrhage - Alma Study |
Principal Investigator(s) 1. Omondi Ogutu Site(s) in Kenya Kenyatta National Hospital |
View |
294. |
ECCT/22/01/04 | SKYSCRAPER 07 A PHASE III, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF ATEZOLIZUMAB WITH OR WITHOUT TIRAGOLUMAB (ANTI-TIGIT ANTIBODY) IN PATIENTS WITH UNRESECTABLE ESOPHAGEAL SQUAMOUS CELL CARCINOMA WHOSE CANCERS HAVE NOT PROGRESSED FOLLOWING DEFINITIVE CONCURRENT CHEMORADIOTHERAPY |
Principal Investigator(s) 1. Fredrick Chite Asirwa 2. Mansoor Saleh Site(s) in Kenya 1. Aga Khan University, Nairobi (Nairobi City county) 2. International Cancer Institute (Uasin Gishu county) |
View |
295. |
ECCT/24/02/06 | INAVO122 A phase III, multicenter, randomized, double-blind, placebo-controlled study evaluating the efficacy and safety of Inavolisib in combination with Phesgo versus placebo in combination with Phesgo as maintenance therapy after first line induction therapy in participants with PIK3CA‐mutated HER2‐positive locally advanced or metastatic breast cancer |
Principal Investigator(s) 1. Dr Sitna Ali Site(s) in Kenya University of Nairobi -Institute of Tropical and Infectious Diseases |
View |